A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis

Genes Chromosomes and Cancer

Volumn 52, Issue 10, 2013, Pages 961-975

  Eifert, Cheryl ^a,c   Wang, Xianhui ^a   Kokabee, Leila ^a   Kourtidis, Antonis ^a   Jain, Ritu ^a   Gerdes, Michael J ^b   Conklin, Douglas S ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b GE GLOBAL RESEARCH   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; DOXORUBICIN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL MATURATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RNA INTERFERENCE;

APOPTOSIS; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE;

EID: 84883003563     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22091     Document Type: Article

References (54)

1. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D, Theillet C. 1991. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6:659-663.
2. Archey WB, Sweet MP, Alig GC, Arrick BA. 1999. Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3. Cancer Res 59:2292-2296.
3. Backesjo CM, Vargas L, Superti-Furga G, Smith CI. 2002. Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem Biophys Res Commun 299:510-515.
4. Baselga J. 2006. Targeting tyrosine kinases in cancer: The second wave. Science 312:1175-1178.
5. Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA. 2008. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol 173:1540-1550.
6. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355-365.
7. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. 2005. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. Faseb J 19:1884-1886.
8. Cameron HL, Foster WG. 2008. Dieldrin promotes resistance to anoikis in breast cancer cells in vitro. Reprod Toxicol 25:256-262.
9. Cha JY, Lambert QT, Reuther GW, Der CJ. 2008. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6:435-445.
10. Chan SK, Hill ME, Gullick WJ. 2006. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 11:3-11.
11. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ, Borowsky AD, Kung HJ, Wei G, Ostrowski MC, Brodie A, Qiu Y. 2006. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 66:8058-8064.
12. Davuluri RV, Suzuki Y, Sugano S, Plass C, Huang TH. 2008. The functional consequences of alternative promoter use in mammalian genomes. Trends Genet 24:167-177.
13. de Weers M, Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ, Hendriks RW. 1993. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 23:3109-3114.
14. Down TA, Hubbard TJ. 2002. Computational detection and location of transcription start sites in mammalian genomic DNA. Genome Res 12:458-461.
15. Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K, Ahmed SS, Stebbing J, Knippschild U. 2010. Kinases as targets in the treatment of solid tumors. Cell Signal 22:984-1002.
16. Gomes IM, Maia CJ, Santos CR. 2012. STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res 10:573-587.
17. Griffiths-Jones S. 2004. The microRNA Registry. Nucleic Acids Res 32:D109-111.
18. Grunewald TG, Bach H, Cossarizza A, Matsumoto I. 2012. The STEAP protein family: Versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol Cell 104:641-657.
19. Harada N, Utsumi T, Takagi Y. 1993. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90:11312-11316.
20. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG. 2002. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 359:481-486.
21. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075-13080.
22. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr., Hoover RN, Thomas G, Chanock SJ. 2007. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870-874.
23. Irish JM, Czerwinski DK, Nolan GP, Levy R. 2006. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108:3135-3142.
24. Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP. 2007. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem 282:32689-32698.
25. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563.
26. Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T, Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T, Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S. 2006. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 16:55-65.
27. Kourtidis A, Eifert C, Conklin DS. 2007. RNAi applications in target validation. Ernst Schering Res Found Workshop:1-21.
28. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
29. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158.
30. Kuppers R. 2005. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251-262.
31. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC. 2007. The diploid genome sequence of an individual human. PLoS Biol 5:e254.
32. Li TW, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M, Waterman ML. 2006. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol 26:5284-5299.
33. Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R, Aulabaugh A, Stahl M. 2009. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity. Biochemistry 48:2021-2032.
34. MacKeigan JP, Murphy LO, Blenis J. 2005. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7:591-600.
35. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B, Michael H, Munch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, Wingender E. 2003. TRANSFAC: Transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31:374-378.
36. Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, Smith CI. 2009. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228:58-73.
37. Nahta R, Esteva FJ. 2006. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215.
38. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043-6052.
39. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, deLapeyriere O. 1995. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61:170-176.
40. Qin DN, Zhu JG, Ji CB, Chunmei S, Kou CZ, Zhu GZ, Zhang CM, Wang YP, Ni YH, Guo XR. 2011. Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13K (P85) and Akt: Possible mitochondrial mechanism. J Bioenerg Biomembr 43:247-255.
41. Qiu Y, Kung HJ. 2000. Signaling network of the Btk family kinases. Oncogene 19:5651-5661.
42. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL. 2005. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 102:11005-11010.
43. Ruschel A, Ullrich A. 2004. Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. Cell Signal 16:1249-1261.
44. Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F. 2011. Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer 10:86.
45. Shepard HM, Brdlik CM, Schreiber H. 2008. Signal integration: A framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118:3574-3581.
46. Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, McCombie WR, Cleary MA, Elledge SJ, Hannon GJ. 2005. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:1281-1288.
47. Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS, Kjellen P, Lambris JD, Christensson B, Hammarstrom L et al., 1994. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 152:557-565.
48. Srinivasan D, Plattner R. 2006. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66:5648-5655.
49. Srinivasan D, Sims JT, Plattner R. 2008. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27:1095-1105.
50. Thorsen K, Schepeler T, Oster B, Rasmussen MH, Vang S, Wang K, Hansen KQ, Lamy P, Pedersen JS, Eller A, Mansilla F, Laurila K, Wiuf C, Laurberg S, Dyrskjot L, Orntoft TF, Andersen CL. 2011. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics 12:505.
51. Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. 1999. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 274:1646-1656.
52. Vassilev AO, Uckun FM. 2004. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr Pharm Des 10:1757-1766.
53. Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E, Casado LF, Martinez J, Martinez P, Lombardia L, Villalon L, Odriozola J, Piris MA. 2006. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 20:1047-1054.
54. Winer ES, Ingham RR, Castillo JJ. 2012. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 21:355-361.